The US Centers for Medicare and Medicaid Service’s plan to increase Medicare coverage for home infused drugs during the COVID-19 pandemic is unlikely to provide a meaningful increase in access, according to infusion providers and other health care stakeholders.
The plan is part of an interim final rule released in late March. It would broaden the number of Part...







